Revenue growth and improved operating leverage drives 27% increase in
adjusted operating income. GAAP results impacted by productivity and
consolidation initiatives, which are expected to drive improved
profitability.
FRISCO, Texas--(BUSINESS WIRE)--Oct. 25, 2012--
Greatbatch, Inc. (NYSE: GB), today announced results for its third
quarter ended September 28, 2012:
-
Sales increased 22% over the prior year to $161.3 million and included
8% organic constant currency growth, as well as additional revenue
from our acquisitions:
-
CRM/Neuromodulation product line revenue increased 13%.
-
Portable Medical product line benefiting from new product
introductions.
-
20% Vascular Access growth driven by commercialization of medical
devices.
-
Orthopaedics constant currency revenue declined 6%; continues to
be negatively impacted by operational issues at our Swiss
facilities, which are aggressively being addressed.
-
Third quarter GAAP operating income of $2.1 million and diluted EPS
loss of $0.32 per share decreased versus the prior year primarily due
to charges incurred in connection with the consolidation of our Swiss
Orthopaedic operations, which are ultimately expected to improve
profitability beginning in 2013.
-
Adjusted operating income increased 27% over the prior year due to
revenue growth and improved operating leverage. This increase resulted
in adjusted diluted EPS of $0.46 per share for the third quarter, 12%
above the prior year.
-
Cash flows from operations were $16 million for the third quarter,
which enabled the Company to pay down an additional $6 million of
long-term debt.
|
|
|
|
|
|
|
|
|
Three Months Ended
|
(Dollars in thousands, except per share data)
|
|
|
|
September 28,
|
|
September 30,
|
|
%
|
|
June 29,
|
|
%
|
|
|
|
2012
|
|
2011
|
|
Change
|
|
2012
|
|
Change
|
Sales
|
|
|
|
$
|
161,340
|
|
$
|
131,718
|
|
22%
|
|
$
|
166,548
|
|
-3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Operating Income
|
|
|
|
$
|
2,127
|
|
$
|
12,888
|
|
-83%
|
|
$
|
11,091
|
|
-81%
|
GAAP Operating Income as % of Sales
|
|
|
|
|
1.3%
|
|
|
9.8%
|
|
|
|
|
6.7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Operating Income*
|
|
|
|
$
|
18,664
|
|
$
|
14,714
|
|
27%
|
|
$
|
18,589
|
|
0%
|
Adjusted Operating Income as % of Sales
|
|
|
|
|
11.6%
|
|
|
11.2%
|
|
|
|
|
11.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP Diluted EPS
|
|
|
|
$
|
(0.32)
|
|
$
|
0.30
|
|
N/A
|
|
$
|
0.16
|
|
N/A
|
Adjusted Diluted EPS*
|
|
|
|
$
|
0.46
|
|
$
|
0.41
|
|
12%
|
|
$
|
0.43
|
|
7%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Refer to Tables A and B at the end of this release for a
reconciliation of GAAP to adjusted amounts.
|
|
CEO Comments
“During the quarter, we continued to drive growth in our core business
and benefited from favorable market trends and new product introductions
within our Portable Medical product line,” commented Thomas J. Hook,
President & CEO, Greatbatch Inc. “Additionally, during the quarter, we
continued to deepen our relationship with our larger OEM customers and
successfully negotiated several long-term agreements which secured
existing revenue streams, as well as expanded those relationships into
other product lines. As we move forward, our goal is to continue to
drive core growth through an increased focus on and investment in sales
and marketing and the commercialization of our medical device pipeline.
Additionally, we are focused on further improving profitability by
leveraging our infrastructure and optimizing our R&D investment. I am
pleased with the progress we have made on our strategic objectives and
remain confident that these initiatives will improve the long-term
growth and profitability of our Company.”
CFO Comments
“Our adjusted operating performance continued to improve during the
quarter as we grew our core business, further leveraged our operating
infrastructure, and began to optimize our R&D investment,” commented
Michael Dinkins, Senior Vice President & CFO. “During the quarter, we
also continued to aggressively address the operational issues we are
experiencing at our Swiss Orthopaedic facilities. We continue to move
forward with our consolidation plans as diligently as possible in order
to resolve these issues in a timely and effective manner. As a result of
the progress we have made, we now expect that our adjustments to
non-GAAP operating income for 2012 will be $40 million to $45 million
compared to the $20 million to $30 million estimate provided last
quarter. It is important to note that, while we are increasing the 2012
estimate for these costs, the overall estimate to complete our
consolidation initiatives remains unchanged and the impact to our
operating cash flows will be significantly less than the charges taken.
Even though these charges reduce our GAAP operating results in the near
term, these initiatives will increase operating leverage and
profitability as we move forward.”
Third Quarter Results
Third quarter 2012 sales increased 22% over the prior year period to
$161.3 million. This increase was driven by the results from our
acquisitions, which added $21.6 million to sales, as well as growth of
13% in CRM/Neuromodulation and 20% in Vascular Access revenue. On an
organic constant currency basis, sales for the third quarter increased
8% versus the prior year as the benefits described above were partially
offset by operational issues experienced within our Orthopaedics product
line. Third quarter results also included the impact of foreign currency
exchange rate fluctuations, which lowered Orthopaedic sales by
approximately $2 million in comparison to the prior year.
Gross profit increased $9.0 million to $51.0 million in the third
quarter of 2012, compared to $41.9 million for the comparable 2011
period. This increase in gross profit primarily resulted from the higher
sales volumes discussed above. Gross profit as a percentage of sales for
the current quarter of 31.6% remained consistent with the prior year, as
the benefit of higher production volumes was offset by production
inefficiencies at our Swiss Orthopaedic facilities.
Selling, general and administrative (“SG&A”) expenses increased to $20.3
million for the third quarter of 2012 compared to $17.8 million for the
same period of 2011. This increase is due to the Company’s acquisitions,
which added $2.4 million to SG&A. As a percentage of sales, SG&A
expenses decreased to 12.6% from 13.5% in the prior year as the Company
continues to leverage its existing operating infrastructure.
Net research, development and engineering costs (“RD&E”) for the 2012
third quarter were $13.2 million, compared to $11.1 million for the
comparable 2011 period. Approximately $0.9 million of this increase was
due to the Company’s acquisitions. Additionally, this increase can be
attributed to the investment in the development of complete medical
devices which totaled $6.6 million for the 2012 third quarter compared
to $6.2 million for 2011. These amounts include $1.2 million and $1.6
million, respectively, of design verification testing (“DVT”) costs in
connection with our development of a neuromodulation platform. As
indicated last quarter, we anticipate that RD&E for the second half of
2012 will be lower than the first half of 2012 as the Company begins to
optimize its RD&E investment. In comparison to the second quarter of
2012, net RD&E declined $0.9 million.
GAAP operating income for the third quarter of 2012 was $2.1 million
compared to $12.9 million for the 2011 third quarter. This decrease was
primarily due to the charges incurred in connection with the
consolidation of our Swiss Orthopaedic operations, as well as other
productivity initiatives which are expected to ultimately drive improved
profitability. Adjusted operating income, which excludes the impact of
these charges, was $18.7 million, or 11.6% of sales in the third quarter
of 2012, compared to $14.7 million, or 11.2% of sales, for the
comparable 2011 period. Refer to Table A at the end of this release for
a reconciliation of GAAP operating income to adjusted operating income
and the “Use of Non-GAAP Financial Information” section below.
The GAAP effective tax rate for the first nine months of 2012 was 93.0%
compared to 31.0% for the same period of 2011. This increase was
primarily attributable to approximately $5.0 million of tax charges
recorded in connection with our Swiss Orthopaedic consolidation. These
charges relate to the loss of our Swiss tax holiday, due to our third
quarter 2012 decision to discontinue manufacturing in Switzerland and
the establishment of a valuation allowance on our Swiss deferred tax
assets, as it is more likely than not that they will not be fully
realized. Additionally, our 2012 effective tax rate includes losses from
our Swiss operations, the benefit of which are recorded at a lower
effective tax rate, thus increasing the overall effective tax rate of
the Company, and does not include the benefit of the U.S. R&D tax
credit, which expired at the end of 2011. The provision for income taxes
for the third quarter of 2012 represents the amount necessary to bring
our year-to-date effective tax rate to 93.0% and is based upon our full
year expected GAAP effective tax rate.
GAAP and adjusted diluted EPS for the third quarter of 2012 were a loss
of $0.32 and income of $0.46 per share, respectively, compared to income
of $0.30 and $0.41 per share, respectively, for the third quarter 2011.
Refer to Table B at the end of this release for a reconciliation of GAAP
net income (loss) to adjusted net income and the “Use of Non-GAAP
Financial Information” section below.
Despite significantly lower GAAP net income (loss), cash flows from
operations for the third quarter of 2012 were approximately $16 million
compared to $21 million in the 2011 period as a significant portion of
the charges recorded in 2012 did not result in additional cash
expenditures. During the third quarter of 2012, the Company repaid $6
million of long-term debt.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product Line Sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table summarizes the Company’s sales by major product
lines (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
|
|
September 28,
|
|
|
September 30,
|
|
%
|
|
|
June 29,
|
|
%
|
Product Line
|
|
|
|
|
2012
|
|
|
2011
|
|
Change
|
|
|
2012
|
|
Change
|
Implantable Medical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CRM/Neuromodulation
|
|
|
|
$
|
80,255
|
|
$
|
70,731
|
|
13%
|
|
$
|
80,025
|
|
0%
|
Vascular Access
|
|
|
|
|
13,674
|
|
|
11,396
|
|
20%
|
|
|
12,481
|
|
10%
|
Orthopaedic
|
|
|
|
|
27,163
|
|
|
31,131
|
|
-13%
|
|
|
32,860
|
|
-17%
|
Total Implantable Medical
|
|
|
|
|
121,092
|
|
|
113,258
|
|
7%
|
|
|
125,366
|
|
-3%
|
Electrochem
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Portable Medical
|
|
|
|
|
20,219
|
|
|
1,954
|
|
N/A
|
|
|
20,407
|
|
-1%
|
Energy/Environmental
|
|
|
|
|
16,192
|
|
|
13,955
|
|
16%
|
|
|
16,879
|
|
-4%
|
Other
|
|
|
|
|
3,837
|
|
|
2,551
|
|
50%
|
|
|
3,896
|
|
-2%
|
Total Electrochem
|
|
|
|
|
40,248
|
|
|
18,460
|
|
118%
|
|
|
41,182
|
|
-2%
|
Total Sales
|
|
|
|
$
|
161,340
|
|
$
|
131,718
|
|
22%
|
|
$
|
166,548
|
|
-3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Implantable Medical
Compared to the prior year, CRM and Neuromodulation sales for the third
quarter of 2012 increased 13% to a record $80.3 million due to more
level customer inventory ordering patterns in 2012 in comparison to
2011, as well as easier comparables versus the 2011 period. CRM and
Neuromodulation revenue growth continues to exceed our expectations but
management remains cautiously optimistic over the short-term prospects
of this product line given the ongoing challenges surrounding key OEM
customers. However, our longer term outlook remains optimistic as we
continue to see an increased pace of product development opportunities
from our CRM customers. Management believes that this, combined with our
increased focus on sales and marketing, will allow the Company to grow
this product line faster than the underlying market.
Third quarter 2012 sales for the Vascular Access product line increased
20% to $13.7 million in comparison to the prior year and was primarily
driven by the commercialization of new medical devices.
Orthopaedic sales of $27.2 million for the third quarter of 2012
declined 13% (-6% constant currency) compared to the third quarter of
2011. Foreign currency exchange rate fluctuations decreased Orthopaedic
revenue by approximately $2 million in the third quarter of 2012 in
comparison to the prior year. The remaining decline in third quarter
2012 Orthopaedic sales was a result of fewer customer product launches
and development opportunities due to operational issues within our
Orthopaedic business, which are aggressively being addressed. In
comparison to the sequential second quarter, Orthopaedic revenue
decreased 17% primarily due to the seasonal facility shut-downs in our
European operations.
Electrochem
Third quarter 2012 sales for Electrochem increased $21.8 million to
$40.2 million versus $18.5 million for the comparable 2011 period. Third
quarter 2012 Electrochem sales included $20.9 million of revenue related
to our acquisition. On an organic basis, Electrochem revenue increased
5% in comparison to the prior year. Electrochem revenue continues to
exceed our expectations, which is being driven by successful product
launches into the higher growth Portable Medical market. This market is
benefiting from the shifting of patient care from clinical settings to
the home and an aging population, which is driving the need for
lightweight and portable devices for patients and caregivers. Our funnel
of portable medical products continues to be full and is expected to
drive revenue growth for the next several years.
Financial Guidance
At this time, we are reaffirming our sales guidance provided at the
beginning of the year. Additionally, consistent with last quarter, we
continue to expect our adjusted operating income as a percentage of
sales and adjusted diluted EPS to be at the lower end of the ranges
provided. The guidance provided at the beginning of the year was as
follows:
|
|
|
|
|
Sales
|
|
|
|
$645 million - $665 million
|
Adjusted Operating Income as a % of Sales
|
|
|
|
11.5% - 12.5%
|
Adjusted Diluted EPS
|
|
|
|
$1.75 - $1.85
|
|
|
|
|
|
Adjusted operating income for 2012 is expected to consist of GAAP
operating income minus non-recurring, unusual or infrequently occurring
items such as acquisition, consolidation and integration charges,
certain RD&E expenditures and asset disposition/write-down charges,
totaling approximately $40 million to $45 million, a significant portion
of which are non-cash expenses. This range has been revised upward from
our previous expectations of $20 million to $30 million to reflect the
progress we have made on our numerous productivity and consolidation
initiatives. It is important to note that, while we are increasing the
2012 estimate for these costs, the overall estimate to complete our
consolidation initiatives remains unchanged and the impact to our
operating cash flows will be significantly less than the charges
incurred. Even though these charges reduce our GAAP operating results in
the near term, these initiatives will enable increased operating
leverage and profitability as we move forward.
Adjusted diluted EPS for 2012 is GAAP diluted EPS excluding the
after-tax impact of the adjusted amounts described above and $9.1
million ($5.9 million net of tax) of non-cash convertible debt interest
expense as well as tax charges recorded in connection with the
consolidation of our Swiss Orthopaedic facilities of approximately $7
million to $10 million.
Conference Call
The Company will host a conference call on Thursday October 25, 2012 at
5:00 p.m. ET to discuss these results. The scheduled conference call
will be webcast live and is accessible through the Company’s website at www.greatbatch.com.
An audio replay will also be available beginning from 7:00 p.m. ET on
October 25, 2012 until November 1, 2012. To access the replay, dial
888-286-8010 (U.S.) and enter the passcode 31065955.
About Greatbatch, Inc.
Greatbatch, Inc. (NYSE: GB) provides top-quality technologies to
industries that depend on reliable, long-lasting performance through its
brands Greatbatch Medical, Electrochem and QiG Group. Greatbatch Medical
develops and manufactures critical medical device technologies for the
cardiac, neurology, vascular and orthopaedic markets. Electrochem
designs and manufactures battery and wireless sensing technologies for
high-end niche applications in the portable medical, energy, military,
and other markets. The QiG Group empowers the design and development of
new medical devices for our core markets. Additional information about
the Company is available at www.greatbatch.com.
Use of Non-GAAP Financial Information
In addition to our results reported in accordance with generally
accepted accounting principles (“GAAP”), we provide adjusted operating
income and margin, adjusted net income and adjusted earnings per diluted
share. These adjusted amounts consist of GAAP amounts excluding the
following adjustments to the extent occurring during the period: (i)
acquisition-related charges, (ii) facility consolidation, optimization,
manufacturing transfer and system integration charges, (iii) asset
write-down and disposition charges, (iv) severance charges in connection
with corporate realignments or a reduction in force (v) litigation
charges and gains, (vi) the impact of non-cash charges to interest
expense due to the accounting change for convertible debt, (vii) unusual
or infrequently occurring items, (viii) certain R&D expenditures (such
as medical device DVT expenses in connection with developing our
Neuromodulation platform), (ix) gain/loss on the sale of investments,
(x) the income tax (benefit) related to these adjustments and (xi)
Certain tax charges related to the consolidation of our Swiss
Orthopaedic facility. Adjusted earnings per diluted share were
calculated by dividing adjusted net income for diluted earnings per
share by diluted weighted average shares outstanding. We believe that
the presentation of adjusted operating income and margin, adjusted net
income and adjusted diluted earnings per share provides important
supplemental information to management and investors seeking to
understand the financial and business trends relating to our financial
condition and results of operations.
Forward-Looking Statements
Some of the statements in this press release, including the information
provided under the caption “Financial Guidance,” are “forward-looking
statements” within the meaning of Section 27A of the Securities Act of
1933, as amended, and section 21E of the Securities Exchange Act of
1934, as amended, and involve a number of risks and uncertainties. These
statements can be identified by terminology such as “may,” “will,”
“should,” “could,” “expects,” “intends,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “potential” or “continue,” or the
negative of these terms or other comparable terminology. These
statements are based on the Company’s current expectations. The
Company’s actual results could differ materially from those stated or
implied in such forward-looking statements. Risks and uncertainties that
could cause actual results to differ materially from those stated or
implied by such forward-looking statements include, among others, the
following matters affecting the Company: our dependence upon a limited
number of customers; customer ordering patterns; product obsolescence;
our inability to market current or future products; pricing/vertical
integration pressure from customers; our ability to timely and
successfully implement our cost reduction and plant consolidation
initiatives (including the consolidation of our Swiss Orthopaedic
operations); our reliance on third party suppliers for raw materials,
products and subcomponents; our inability to maintain high quality
standards for our products; challenges to our intellectual property
rights; product liability claims; our inability to successfully
consummate and integrate acquisitions and to realize synergies; our
unsuccessful expansion into new markets; our ability to realize a return
on our substantial RD&E investments, including system and device
products; our inability to obtain licenses to key technology; regulatory
changes or consolidation in the healthcare industry; global economic
factors including currency exchange rates and interest rates; the
resolution of various legal actions and other risks and uncertainties
described in the Company’s Annual Report on Form 10-K and in other
periodic filings with the Securities and Exchange Commission. The
Company assumes no obligation to update forward-looking information in
this press release whether to reflect changed assumptions, the
occurrence of unanticipated events or changes in future operating
results, financial conditions or prospects, or otherwise.
Table A: Operating Income Reconciliation:
|
A reconciliation of GAAP operating income to adjusted amounts is as
follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
|
|
September 28,
|
|
September 30,
|
|
September 28,
|
|
September 30,
|
|
|
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
Operating income as reported
|
|
|
|
$
|
2,127
|
|
$
|
12,888
|
|
$
|
24,416
|
|
$
|
49,157
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventory step-up amortization (COS)
|
|
|
|
|
-
|
|
|
-
|
|
|
532
|
|
|
-
|
Medical device DVT expenses (RD&E)
|
|
|
|
|
1,224
|
|
|
1,639
|
|
|
3,839
|
|
|
2,863
|
Consolidation and optimization costs
|
|
|
|
|
14,778
|
|
|
164
|
|
|
20,801
|
|
|
425
|
Integration expenses
|
|
|
|
|
232
|
|
|
-
|
|
|
1,287
|
|
|
-
|
Asset dispositions, severance and other
|
|
|
|
|
303
|
|
|
23
|
|
|
1,893
|
|
|
(591)
|
Adjusted operating income
|
|
|
|
$
|
18,664
|
|
$
|
14,714
|
|
$
|
52,768
|
|
$
|
51,854
|
Adjusted operating margin
|
|
|
|
|
11.6%
|
|
|
11.2%
|
|
|
10.8%
|
|
|
12.1%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Table B: Net Income (Loss) and Diluted EPS Reconciliation
|
A reconciliation of GAAP net income (loss) and diluted EPS to
adjusted amounts is as follows (in thousands, except per share
amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
|
|
September 28,
|
|
September 30,
|
|
September 28,
|
|
September 30,
|
|
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
Net Income (Loss)
|
|
|
Impact Per Diluted Share
|
|
|
Net Income (Loss)
|
|
|
Impact Per Diluted Share
|
|
|
Net Income (Loss)
|
|
|
Impact Per Diluted Share
|
|
|
Net Income (Loss)
|
|
|
Impact Per Diluted Share
|
Net income (loss) as reported
|
|
|
|
$
|
(7,561)
|
|
$
|
(0.32)
|
|
$
|
6,989
|
|
$
|
0.30
|
|
$
|
757
|
|
$
|
0.03
|
|
$
|
27,483
|
|
$
|
1.16
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inventory step-up amortization (COS)
|
|
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
346
|
|
|
0.01
|
|
|
-
|
|
|
-
|
Medical device DVT expenses (RD&E)
|
|
|
|
|
796
|
|
|
0.03
|
|
|
1,065
|
|
|
0.05
|
|
|
2,495
|
|
|
0.10
|
|
|
1,861
|
|
|
0.08
|
Consolidation and optimization costs(a)
|
|
|
|
|
11,119
|
|
|
0.46
|
|
|
107
|
|
|
-
|
|
|
15,034
|
|
|
0.63
|
|
|
276
|
|
|
0.01
|
Integration expenses
|
|
|
|
|
151
|
|
|
0.01
|
|
|
-
|
|
|
-
|
|
|
837
|
|
|
0.03
|
|
|
-
|
|
|
-
|
Asset dispositions, severance and other
|
|
|
|
|
197
|
|
|
0.01
|
|
|
15
|
|
|
-
|
|
|
1,230
|
|
|
0.05
|
|
|
(384)
|
|
|
(0.02)
|
Gain on cost method investments, net(b)
|
|
|
|
|
(228)
|
|
|
(0.01)
|
|
|
-
|
|
|
-
|
|
|
(228)
|
|
|
(0.01)
|
|
|
(2,751)
|
|
|
(0.12)
|
CSN conversion option discount amortization(c)
|
|
|
|
|
1,498
|
|
|
0.06
|
|
|
1,391
|
|
|
0.06
|
|
|
4,413
|
|
|
0.18
|
|
|
4,097
|
|
|
0.17
|
Swiss tax impact(d)
|
|
|
|
|
5,008
|
|
|
0.21
|
|
|
-
|
|
|
-
|
|
|
5,008
|
|
|
0.21
|
|
|
-
|
|
|
-
|
Adjusted net income and diluted EPS(e)
|
|
|
|
$
|
10,980
|
|
$
|
0.46
|
|
$
|
9,567
|
|
$
|
0.41
|
|
$
|
29,892
|
|
$
|
1.25
|
|
$
|
30,582
|
|
$
|
1.29
|
Adjusted diluted weighted average shares(f)
|
|
|
|
|
24,011
|
|
|
|
|
|
23,611
|
|
|
|
|
|
23,924
|
|
|
|
|
|
23,663
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
|
Net of tax amounts computed using U.S. and foreign statutory tax
rates of 35% and 22.5%, respectively, for items incurred in those
geographic locations.
|
(b)
|
|
Pre-tax amount is $350 thousand for both the quarter and
year-to-date periods for 2012 and $4.2 million for the year-to-date
period of 2011.
|
(c)
|
|
Pre-tax amount is $2.3 million and $6.8 million for the 2012 quarter
and year-to-date periods, respectively, and $2.1 million and $6.3
million for the 2011 quarter and year-to-date periods, respectively.
|
(d)
|
|
Relates to the loss of our Swiss tax holiday due to our decision to
discontinue manufacturing in Switzerland, as well as the
establishment of a valuation allowance on our Swiss deferred tax
assets as it is more likely than not that they will not be fully
realized.
|
(e)
|
|
The per share data in this table has been rounded to the nearest
$0.01 and therefore may not sum to the total.
|
(f)
|
|
Weighted average diluted shares for the third quarter of 2012
includes 365 thousand shares of dilution related to outstanding
stock incentive awards that were not dilutive for GAAP EPS purposes.
|
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - Unaudited
|
(in thousands except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
|
|
|
|
September 28,
|
|
|
September 30,
|
|
|
September 28,
|
|
|
September 30,
|
|
|
|
|
|
2012
|
|
|
2011
|
|
|
2012
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales
|
|
|
|
$
|
161,340
|
|
$
|
131,718
|
|
$
|
486,991
|
|
$
|
427,076
|
Cost of sales
|
|
|
|
|
110,386
|
|
|
89,811
|
|
|
337,216
|
|
|
291,395
|
Gross profit
|
|
|
|
|
50,954
|
|
|
41,907
|
|
|
149,775
|
|
|
135,681
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
|
|
20,274
|
|
|
17,760
|
|
|
60,053
|
|
|
53,980
|
Research, development and engineering costs, net
|
|
|
|
|
13,240
|
|
|
11,072
|
|
|
41,325
|
|
|
32,710
|
Other operating (income) expense, net
|
|
|
|
|
15,313
|
|
|
187
|
|
|
23,981
|
|
|
(166)
|
Total operating expenses
|
|
|
|
|
48,827
|
|
|
29,019
|
|
|
125,359
|
|
|
86,524
|
Operating income
|
|
|
|
|
2,127
|
|
|
12,888
|
|
|
24,416
|
|
|
49,157
|
Interest expense
|
|
|
|
|
4,401
|
|
|
4,125
|
|
|
13,176
|
|
|
12,802
|
Interest income
|
|
|
|
|
-
|
|
|
(1)
|
|
|
(1)
|
|
|
(9)
|
Gain on cost method investments, net
|
|
|
|
|
(350)
|
|
|
-
|
|
|
(350)
|
|
|
(4,232)
|
Other (income) expense, net
|
|
|
|
|
248
|
|
|
(475)
|
|
|
774
|
|
|
766
|
Income (loss) before provision for income taxes
|
|
|
|
|
(2,172)
|
|
|
9,239
|
|
|
10,817
|
|
|
39,830
|
Provision for income taxes
|
|
|
|
|
5,389
|
|
|
2,250
|
|
|
10,060
|
|
|
12,347
|
Net income (loss)
|
|
|
|
$
|
(7,561)
|
|
$
|
6,989
|
|
$
|
757
|
|
$
|
27,483
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
$
|
(0.32)
|
|
$
|
0.30
|
|
$
|
0.03
|
|
$
|
1.18
|
Diluted
|
|
|
|
$
|
(0.32)
|
|
$
|
0.30
|
|
$
|
0.03
|
|
$
|
1.16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
|
|
23,646
|
|
|
23,297
|
|
|
23,559
|
|
|
23,241
|
Diluted
|
|
|
|
|
23,646
|
|
|
23,611
|
|
|
23,924
|
|
|
23,663
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS - Unaudited
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
ASSETS
|
|
|
|
September 28,
|
|
December 30,
|
|
|
|
2012
|
|
2011
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
|
$
|
10,843
|
|
$
|
36,508
|
Accounts receivable, net
|
|
|
|
|
124,803
|
|
|
101,946
|
Inventories
|
|
|
|
|
111,163
|
|
|
109,913
|
Refundable income taxes
|
|
|
|
|
-
|
|
|
1,292
|
Deferred income taxes
|
|
|
|
|
7,261
|
|
|
7,828
|
Prepaid expenses and other current assets
|
|
|
|
|
7,622
|
|
|
7,469
|
Total current assets
|
|
|
|
|
261,692
|
|
|
264,956
|
Property, plant and equipment, net
|
|
|
|
|
156,662
|
|
|
145,806
|
Amortizing intangible assets, net
|
|
|
|
|
91,065
|
|
|
100,258
|
Indefinite-lived intangible assets
|
|
|
|
|
20,828
|
|
|
20,288
|
Goodwill
|
|
|
|
|
347,803
|
|
|
338,653
|
Deferred income taxes
|
|
|
|
|
2,106
|
|
|
2,450
|
Other assets
|
|
|
|
|
11,774
|
|
|
8,936
|
Total assets
|
|
|
|
$
|
891,930
|
|
$
|
881,347
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
|
|
$
|
44,146
|
|
$
|
40,665
|
Income taxes payable
|
|
|
|
|
2,932
|
|
|
-
|
Deferred income taxes
|
|
|
|
|
1,244
|
|
|
845
|
Accrued expenses
|
|
|
|
|
43,992
|
|
|
52,539
|
Total current liabilities
|
|
|
|
|
92,314
|
|
|
94,049
|
Long-term debt
|
|
|
|
|
230,154
|
|
|
235,950
|
Deferred income taxes
|
|
|
|
|
78,290
|
|
|
75,203
|
Other long-term liabilities
|
|
|
|
|
10,506
|
|
|
8,862
|
Total liabilities
|
|
|
|
|
411,264
|
|
|
414,064
|
Stockholders’ equity:
|
|
|
|
|
|
|
|
|
Preferred stock
|
|
|
|
|
-
|
|
|
-
|
Common stock
|
|
|
|
|
24
|
|
|
23
|
Additional paid-in capital
|
318,032
|
|
|
307,196
|
Treasury stock
|
|
|
|
|
-
|
|
|
(1,387)
|
Retained earnings
|
|
|
|
|
153,279
|
|
|
152,522
|
Accumulated other comprehensive income
|
|
|
|
|
9,331
|
|
|
8,929
|
Total stockholders’ equity
|
|
|
|
|
480,666
|
|
|
467,283
|
Total liabilities and stockholders’ equity
|
|
|
|
$
|
891,930
|
|
$
|
881,347
|
|
|
|
|
|
|
|
|
|
Source: Greatbatch, Inc.
Greatbatch, Inc.
Marco Benedetti, (716) 759-5856
Vice
President Financial Planning and Analysis, Investor Relations & Treasurer
mbenedetti@greatbatch.com